INS and metabolic dysfunction-associated steatotic liver disease: NAFLD is not only the most common chronic liver disease currently, but also its prevalence is doubled in patients with T2DM [4] and due to the increased IR, decreased insulin clearance [18–20] and the key metabolic functions of the liver the presence of NAFLD is a crucial factor in the speed-up of the metabolic deterioration in T2DM development and worsening of atherogenic dyslipidaemia [5, 21, 22].